Champions Oncology Reports Quarterly Revenue of $5.1 Million

Champions Oncology Reports Quarterly Revenue of $5.1 Million

Champions Oncology Reports Quarterly Revenue of $5.1 Million  Company Generates Positive Cash Flow from Operations; Reiterates... READ MORE

Champions Oncology to Participate at the 30th Annual ROTH Conference

Champions Oncology to Participate at the 30th Annual ROTH Conference

Hackensack, NJ – February 26, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced... READ MORE

Motivated Patients with ROS1 Cancer Initiate Global Research Study

Motivated Patients with ROS1 Cancer Initiate Global Research Study

Patients with a rare tumor help drive a novel clinical study developed and launched by the Addario Lung Cancer Medical Institute... READ MORE

Champions Oncology Reports Record Quarterly Revenue of $5.2 Million

Champions Oncology Reports Record Quarterly Revenue of $5.2 Million

Quarterly operating profit driven by double-digit revenue growth Hackensack, NJ – December 7, 2017 – Champions Oncology,... READ MORE

Champions Oncology announces $2 million award from the National Cancer Institute (NCI) to develop and evaluate prostate cancer PDX models

Champions Oncology announces $2 million award from the National Cancer Institute (NCI) to develop and evaluate prostate cancer PDX models

HACKENSACK, NJ - September 26, 2017 - Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development and... READ MORE

Champions Oncology announces publication highlighting clinical correlation between patient-derived xenograft (PDX) model responses and patient responses to oncology therapies

Champions Oncology announces publication highlighting clinical correlation between patient-derived xenograft (PDX) model responses and patient responses to oncology therapies

HACKENSACK, NJ - September 18, 2017 - Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development and... READ MORE

Champions Oncology Reports Record Quarterly Revenue of $5 Million

Champions Oncology Reports Record Quarterly Revenue of $5 Million

37.1% year-over-year revenue increase Hackensack, NJ – September 14, 2017 – Champions Oncology, Inc. (Nasdaq : CSBR)... READ MORE

Champions Oncology Announces Strategic Collaboration with AstraZeneca to Develop Unique Cohorts of Patient-Derived Xenograft (PDX) Models

Champions Oncology Announces Strategic Collaboration with AstraZeneca to Develop Unique Cohorts of Patient-Derived Xenograft (PDX) Models

HACKENSACK, NJ - August 21, 2017 /PRNewswire/ - Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development... READ MORE